Demographic characteristics and patterns of biologic therapies of patients with rheumatoid arthritis (RA).

<p>(<i>N</i> = 2,425).</p

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

<p>Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.</p

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

<p>Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.</p

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.

<p>Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.</p

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

<p>Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.</p